COPD management. Part I. Strategies for managing the burden of established COPD

International Journal of Tuberculosis and Lung Disease

Volumn 12, Issue 6, 2008, Pages 586-594

  Jenkins, C ^a  

^a WOOLCOCK INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

COPD; Exacerbations; Management; Treatment

Indexed keywords

ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; INFLUENZA VACCINE; IPRATROPIUM BROMIDE; PREDNISONE; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE;

AIR POLLUTION; AIRWAY OBSTRUCTION; ANXIETY; ARTIFICIAL VENTILATION; BACTERIAL INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DUST; EXERCISE; HEALTH STATUS; HOSPITAL ADMISSION; HUMAN; NUTRITION; OXYGEN THERAPY; PHYSIOTHERAPY; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY FAILURE; REVIEW; RISK ASSESSMENT; SMOKING CESSATION; SPIROMETRY; SURVIVAL; SYMPTOM;

ADRENAL CORTEX HORMONES; BRONCHODILATOR AGENTS; COMORBIDITY; DIAGNOSIS, DIFFERENTIAL; HOSPITALIZATION; HUMANS; OXYGEN INHALATION THERAPY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; SMOKING CESSATION;

EID: 45349083925     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Spencer S, Calverley P M, Burge P S, Jones P W. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004; 23: 698-702.
2. Soler-Catalina J J, Martinez-Garcia M A, Roman-Sanchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 935-931.
3. Buist A S, McBurnie M A, Vollmer W M, et al. International variation in the prevalence of COPD (the BOLD study): a population-based prevalence study. Lancet 2007; 370: 741-750.
4. Rabe K F, Hurd S, Azueto A, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555.
5. Lundbäck B, Lindberg W A, Lindström M, et al. Not 15 but 50% of smokers develop COPD? Report from the Obstructive Lung Disease in Northern Sweden studies. Respir Med 2003; 97: 115-122.
6. Calverley P M A, Rennard S I. What have we learned from large drug treatment trials in COPD? Lancet 2007; 370: 774-784.
7. O'Donnell D E, Lam M, Webb K A. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 542-549.
8. Celli B R, Halbert R J, Isonaka S, Schauz B. Population impact of different definitions of airway obstruction. Eur Respir J 2003; 22: 268-273.
9. Ruse C, Andrew W, Molyneux P. A study of the management of COPD according to established guidelines and the implications for older patients. Age Ageing 2003; 32: 299-301.
10. Matheson M C, Benke G, Raven J, et al. Biological dust exposure in the work place is a risk factor for chronic obstructive pulmonary disease. Thorax 2005; 60: 645-651.
11. Ezzati M. Indoor air pollution and health in developing countries. Lancet 2005; 366: 104-106.
12. Anthonisen N R, Connett J E, Murray R P, et al. Smoking and lung function in the Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166: 675-679.
13. Burrows B, Knudson R J, Klein M G, Leibowitz M D. Quantitative relationships between cigarette smoking and ventilatory function. Am Rev Respir Dis 1977; 115: 195-205.
14. Anthonisen N R, Skeans M A, Wise R A, et al. The effects of smoking cessation intervention on 14.5 year mortality: a randomized clinical trial. Ann Intern Med 2005; 142: 233-239.
15. He J-Q, Ruan J, Connett J E, et al. Antioxidant gene polymorphisms and susceptibility to a rapid decline in lung function in smokers. Am J Respir Crit Care Med 2002; 166: 323-328.
16. Silverman E K, Speizer F B. Risk factors for the development of chronic obstructive pulmonary disease. Med Clin North Am 1996; 80: 501-502.
17. Ko F W S, Tarn W, Wong T W, et al. Temporal relationship between air pollutants and hospital admissions for chronic obstructive pulmonary disease in Hong Kong. Thorax 2007; 62: 780-785.
18. Chapman R S, Xingzhou H, Blair A E, Lan Q. Improvement in household stoves and risk of chronic obstructive pulmonary disease in Xuanwei, China: retrospective cohort study. BMJ 2005; 331: 1050-1053.
19. Tengs T O, Adams M E, Pliskin J S, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995; 15: 369-390.
20. Willemse B W M, Postma D S, Timens W, ten Hacken N H T. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J 2004; 23: 464-476.
21. Tashkin D, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001; 357: 1571-1575.
22. World Health Organization. WHO framework convention on tobacco control. LC/NLM classification: HD 9130.6. Geneva, Switzerland: WHO 2003, updated reprint 2004, 2005. http://www.who.int/tobacco/framework/en/ Accessed February 2008.
23. Tønnesen P, Carrozzi L, Fagerström K O, et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur Respir J 2007; 29: 390-417.
24. Lindholm L H, Ekborn T, Dash C, et al. The impact of health care advice given in primary care on cardiovascular risk. BMJ 1995; 310: 1105-1109.
25. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004:CD00146.
26. Fiore M C, Bailey W C, Cohen S J. Smoking cessation: information for specialists. Rockville, MD, USA: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research and Centers for Disease Control and Prevention, 1996.
27. Jorenby D E, Hays J T, Rigotti N A, et al. Efficacy of varenicline, an alpha-4 beta-2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 56-63.
28. The tobacco use and dependence clinical practice guideline panel, staff, and consortium representatives. A clinical practice guideline for treating tobacco use and dependence. JAMA 2000; 28: 3244-3254.
29. Guyatt G H, Townsend M, Pugsley S O, et al. Bronchodilators in chronic airflow limitation: effects on airway function, exercise capacity and quality of life. Am J Respir Crit Care Med 1987; 135: 1069-1074.
30. Combivent Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and al-buterol is more effective than either agent alone. An 85 day multicenter trial. Chest 1994; 105: 1411-1419.
31. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399-404.
32. Vincken W, van Noord J A, Greefhorst A P, et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur Respir J 2002; 19: 209-216.
33. Cazzola M, Matera M G, Santangelo G, et al. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose response study. Respir Med 1995; 89: 357-362.
34. O'Donnell D E, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance and COPD. Eur Respir J 2004; 23: 832-840.
35. Donahue J M, van Nord J A, Bateman E F, et al. A six-month placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55.
36. Jenkins S C, Heaton R W, Fulton T J, Moxham J. Comparison of domiciliary nebulized salbutamol and salbutamol from a metered dose inhaler in stable chronic airflow limitation. Chest 1997; 91: 804-807.
37. Alsaeedi A, Sin D D, McAlister F A. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. JAMA 2002; 113: 59-65.
38. Highland K P, Strange C, Heffner J E. Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. Ann Int Med 2003; 138: 969-973.
39. Wouters E F, Postma D S, Fokkens B, et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomized controlled trial. Thorax 2005; 60: 480-487.
40. Sin D D, Tu J V. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 580-584.
41. Sin D D, Wu L, Anderson J A, Anthonisen N R, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60: 992-997.
42. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2003; 361: 449-456.
43. Calverley P M, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912-919.
44. Calverley P M, Anderson J A, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
45. Ernst P, Gonzalez V A, Brasssard P, Suissa S. Inhaled cortico-steroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176: 162-166.
46. Troosters T, Casaburi R, Gosselink R, Decramer M. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 19-38.
47. Gadoury M-A, Schwartzman K, Rouleau M, et al. Self-management reduces both short- and long-term hospitalisation in COPD. Eur Respir J 2005; 26: 853-857.
48. Ries A L, Kaplan R M, Myers R, Prewitt L M. Maintenance after pulmonary rehabilitation in chronic lung disease: a randomized trial. Am J Respir Crit Care Med 2003; 167: 880-888.
49. Ram F S F, Wedzicha J A. Ambulatory oxygen for chronic obstructive pulmonary disease [Cochrane review]. The Cochrane Database of Systematic Reviews 2002, CD 000238.
50. Gorecka D, Gorzelak K, Swilinski P, et al. Effect of long-term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxemia. Thorax 1997; 52: 674-679.
51. Nichol K L, Noordin J, Mollooly J, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003; 348: 1322-1332.
52. Schols A M, Slangen J, Volovics L, Wouters E F. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1791-1797.
53. Laurin C, Lavoie K L, Bacon S L, et al. Sex differences in the prevalence of psychiatric disorders and psychological distress in patients with COPD. Chest 2007; 132: 148-155.
54. Lacasse Y, Rousseau L, Maltais F. Prevalence of depressive symptoms and depression in patients with severe oxygen dependent chronic obstructive pulmonary disease. J Cardiopulm Rehab 2001; 21: 80-86.
55. Fabbri L M, Luppi F, Beghe B, Rabe K F. Complex chronic co-morbidities of COPD. Eur Respir J 2008; 31: 214-212.
56. Rodriguez-Roisin R. Towards a consensus definition for COPD exacerbations. Chest 2000; 117 (Suppl): S398-S401.
57. Seemungal T A, Donaldson G C, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1608-1613.
58. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 1618-1623.
59. Murphy T F, Sethi S, Klingman K L, Brueggeman A B, Doerrn G V. Simultaneous respiratory tract colonization by multiple strains of nontypeable Haemophilus influenzae in chronic obstructive pulmonary disease: implications for antibiotic therapy. J Infect Dis 1999; 118: 404-409.
60. Miravitlles M, Espinosa C, Fernandez-Laso E, et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study group of bacterial infection in COPD. Chest 1999; 116: 40-46.
61. Wilkinson T M, Donaldson G C, Hurst J R, Seemungal T A, Wedzicha J A. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: 1298-1303.
62. Monninkhof E, van der Valk P, van der Palen J, van Herwaarden C, Zielhuis G. Effects of a comprehensive self-management programme in patients with chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 815-820.
63. Niewoehner D E, Erbland M L, Deupree R H, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999; 340: 1941-1947.
64. Adams S J M, Luther M. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of chronic obstructive pulmonary disease. Chest 2000; 117: 1345-1352.
65. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 1995; 273: 957-960.
66. Taylor S J, Candy B, Bryar R M, et al. Effectiveness of innovations in nurse led chronic disease management for patients with chronic obstructive pulmonary disease: systematic review of evidence. BMJ 2005; 331: 485.
67. Bourbeau J, Julien M, Maltais F, et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self management intervention. Arch Intern Med 2003; 163: 585-591.
68. Ojoo J C, Moon T, McGlone S, et al. Patients' and carers' preferences in two models of care for acute exacerbations of COPD: results of a randomised controlled trial. Thorax 2002; 57: 167-169.
69. Lightowler J V, Wedzicha J A, Elliott M W, Ram F S. Noninvasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. BMJ 2003; 326: 185.
70. Plant P K, Owen J L, Elliott M W. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. Lancet 2000; 355: 1931-1935.